Gary Tozbikian

Gary Tozbikian

Auto-generated profile, based on publicly available information

Gary Tozbikian

Department of Pathology, The Ohio State University, Columbus, OH, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GTGary Tozbikian
Gary Tozbikian
EBEdi Brogi
Edi Brogi
KKKyuichi Kadota
Kyuichi Kadota
JCJeffrey Catalano
Jeffrey Catalano
MAMuzaffar Akram
Muzaffar Akram
HWHannah Yong Wen
Hannah Yong Wen
Mesothelin is a cell surface associated antigen expressed on mesothelial cells and in some malignant neoplasms. Mesothelin-targeted therapies are in phase I/II clinical trials. The clinicopathologic and prognostic significance of mesothelin expression in triple negative breast carcinomas (TNBC) has not been fully assessed. We evaluated the expression of mesothelin and of basal markers in tissue microarrays of 226 TNBC and 88 non-TNBC and assessed the clinicopathologic features of mesothelin-expressing breast carcinomas. Furthermore, we investigated the impact of mesothelin expression on the disease-free and overall survival of patients with TNBC. We found that mesothelin expression is significantly more frequent in TNBC than in non-TNBC (36% vs 16%, respectively; p = 0.0006), and is significantly correlated with immunoreactivity for basal keratins, but not for EGFR. Mesothelin-positive and mesothelin-negative TNBC were not significantly different by patients’ race, tumor size, histologic grade, tumor subtype, lymphovascular invasion and lymph node metastases. Patients with mesothelin-positive TNBC were older than patients with mesothelin-negative TNBC, developed more distant metastases with a shorter interval, and had significantly lower overall and disease-free survival. Based on our results, patients with mesothelin-positive TNBC could benefit from mesothelin-targeted therapies.

1 March 2019 in Human Pathology
Verified
Journal Article
Closed access
GTGary H. Tozbikian
Gary H. Tozbikian
DZDebra L. Zynger
Debra L. Zynger

9 May 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CSCaglar Senaras
Caglar Senaras
MNMuhammad Khalid Khan Niazi
Muhammad Khalid Khan Niazi
BSBerkman Sahiner
Berkman Sahiner
MPMichael P Pennell
Michael P Pennell
GTGary Tozbikian
Gary Tozbikian
Metin N. GurcanMetin N. Gurcan
Metin N. Gurcan
In pathology, Immunohistochemical staining (IHC) of tissue sections is regularly used to diagnose and grade malignant tumors. Typically, IHC stain interpretation is rendered by a trained pathologist using a manual method, which consists of counting each positively- and negatively-stained cell under a microscope. The manual enumeration suffers from poor reproducibility even in the hands of expert pathologists. To facilitate this process, we propose a novel method to create artificial datasets with the known ground truth which allows us to analyze the recall, precision, accuracy, and intra- and inter-observer variability in a systematic manner, enabling us to compare different computer analysis approaches. Our method employs a conditional Generative Adversarial Network that uses a database of Ki67 stained tissues of breast cancer patients to generate synthetic digital slides. Our experiments show that synthetic images are indistinguishable from real images. Six readers (three pathologists and three image analysts) tried to differentiate 15 real from 15 synthetic images and the probability that the average reader would be able to correctly classify an image as synthetic or real more than 50% of the time was only 44.7%.

20 May 2016 in BMC Dermatology
Verified
Journal Article
Open access
PDF file
GSGina P. Spohn
Gina P. Spohn
STShannon C. Trotter
Shannon C. Trotter
GTGary Tozbikian
Gary Tozbikian
SPStephen P. Povoski
Stephen P. Povoski
Nipple adenoma is a very uncommon, benign proliferative process of lactiferous ducts of the nipple. Clinically, it often presents as a palpable nipple nodule, a visible nipple skin erosive lesion, and/or with discharge from the surface of the nipple skin, and is primarily seen in middle-aged women. Resultantly, nipple adenoma can clinically mimic the presentation of mammary Paget’s disease of the nipple. The purpose of our current case report is to present a comprehensive review of the available data on nipple adenoma, as well as provide useful information to health care providers (including dermatologists, breast health specialists, and other health care providers) who evaluate patients with dermatologic conditions of the breast skin for appropriately clinically recognizing, diagnosing, and treating patients with nipple adenoma. Fifty-three year old Caucasian female presented with a one year history of erythema and induration of the skin of the inferior aspect of the right nipple/areolar region. Skin punch biopsies showed subareolar duct papillomatosis. The patient elected to undergo complete surgical excision with right central breast resection. Final histopathologic evaluation confirmed nipple adenoma. The patient is doing well 31 months after her definitive surgical therapy. Since nipple adenoma represents a benign proliferative process of the nipple, complete surgical excision is curative. However, the coexistence of nipple adenoma and ipsilateral or contralateral breast cancer is well reported in the literature. The potential for a direct causal link or association of nipple adenoma and breast cancer cannot be fully excluded.

8 April 2019 in American Journal of Clinical Pathology
Verified
Journal Article
Closed access
AGAdlin M Gordian-Arroyo
Adlin M Gordian-Arroyo
DZDebra L Zynger
Debra L Zynger
GTGary H Tozbikian
Gary H Tozbikian
Objectives: The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) human epidermal growth factor receptor 2 (HER2) guideline focused update revises the HER2 scoring criteria. We evaluated the impact on HER2 rates in breast carcinoma diagnosed at our center.Methods: In a retrospective series of breast core biopsies with invasive carcinoma diagnosed between 2014 and 2017 (n = 1,350), HER2 status was classified according to 2013 and 2018 ASCO/CAP guidelines and changes in HER2 status identified.Results: The 2018 guidelines reclassified the HER2 status of 6% of patients. Most changed from HER2 equivocal status (equivocal by immunohistochemistry and fluorescence in situ hybridization under the 2013 guidelines) to HER2-negative status (2018 guidelines). The HER2-positive rate decreased by 0.4%.Conclusions: The 2018 guidelines decrease the rate of HER2 equivocal and positive breast cancer and reduce repeat HER2 testing on excision specimens. Approximately 0.4% of patients will become newly ineligible for anti-HER2 therapy.

4 August 2016 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
PDF file
GTGary Tozbikian
Gary Tozbikian
EBEdi Brogi
Edi Brogi
CVChristina E. Vallejo
Christina E. Vallejo
DGDilip Giri
Dilip Giri
MMMelissa Murray
Melissa Murray
HWHannah Yong Wen
Hannah Yong Wen
Background. The clinical implications of the diagnosis of atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) are very different. Yet there are “borderline” breast lesions that have characteristics of both ADH and DCIS. We examined interobserver diagnostic variability for such lesions and correlated pathologic features of the lesions with clinical outcomes. Methods. We identified all cases of borderline ADH/DCIS lesions treated at our center from 1997 to 2010. Five specialized breast pathologists blinded to clinical outcomes independently reviewed all available slides from each case and were instructed to classify each as benign, ADH, or DCIS. A majority diagnosis (MajDx) was defined as a diagnosis agreed upon by ≥3 pathologists. Results. A total of 105 women with borderline ADH/DCIS and slides available for review were identified. The MajDx was ADH in 84 (80%), and DCIS in 18 (17%). There were split diagnoses in 3 (3%). MajDx of DCIS correlated significantly with lesion size and nuclear grade. There was diagnostic agreement by all 5 pathologists in 30% of cases, 4 pathologists in 42%, and 3 pathologists in 25%. At a median follow-up of 37 months, 4 (3.8%) patients developed subsequent ipsilateral breast carcinoma (2 invasive, 2 DCIS); all 4 cases had MajDx of ADH. Conclusions. Borderline ADH/DCIS represents an entity for which reproducible categorization as ADH or DCIS cannot be achieved. Furthermore, histologic features of borderline lesions resulting in MajDx of ADH vs. DCIS are not prognostic for risk of subsequent breast carcinoma.